The Valley Desk

Clinical trial reportProstate cancer and prostatic diseasesPublished

Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumab

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Thomas Jefferson University. Affiliation source

Publication record

Type
Clinical trial report
Venue
Prostate cancer and prostatic diseases
Published
Subject terms
Humans; Neoplasm Metastasis; Prednisone; Antineoplastic Combined Chemotherapy Protocols; Prognosis; Aged; Middle Aged; Male; Prostatic Neoplasms, Castration-Resistant; Biomarkers, Tumor; Bevacizumab; Docetaxel
PubMed ID
38347114
PubMed Central ID
PMC11317541
Added to directory
Source checked

Report a correction or request removal